Literature DB >> 6607265

Salt loss in hypertensive form of congenital adrenal hyperplasia (11-beta-hydroxylase deficiency).

Z Zadik, L Kahana, H Kaufman, A Benderli, Z Hochberg.   

Abstract

Studies in patients with congenital adrenal hyperplasia due to 11-hydroxylase deficiency (11-OHD) suggest a common defect in the adrenal zona fasciculate and zona glomerulosa. The hypertension in untreated 11-OHD patients is considered to be secondary to the accumulation of deoxycorticosterone as a consequence of inadequate 11-beta-hydroxylation in the biosynthesis of aldosterone, and is alleviated by glucocorticoid suppression. To investigate whether deoxycorticosterone suppression in these patients resulted in loss of salt, 11 patients with 11-OHD aged 4-26 yr were studied. Patients were evaluated during dexamethasone suppression (0.6 mg/m for 2 weeks) while receiving a normal diet and a low salt diet (10 meq Na/24 h). There was no significant change in serum electrolytes, cortisol, 11-deoxycortisol, and DOC during these two dietary regimens. PRA in the recumbent and upright positions on both diets was significantly higher in the patients than in normal subjects. Plasma or urinary aldosterone levels were significantly lower in the 11-OHD patients than in the normal controls. Moderate salt loss occurred during the low salt diet. It is concluded that sodium retention is incomplete in glucocorticoid-treated 11-OHD patients. Partial sodium retention is maintained by increased PRA and a subnormal aldosterone response. 11-OHD patients should be carefully monitored during acute disease states and, when electrolyte imbalance is suspected, treatment with mineralocorticoid should be considered.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6607265     DOI: 10.1210/jcem-58-2-384

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

Review 1.  Clinical perspectives in congenital adrenal hyperplasia due to 11β-hydroxylase deficiency.

Authors:  Krupali Bulsari; Henrik Falhammar
Journal:  Endocrine       Date:  2016-12-07       Impact factor: 3.633

2.  Congenital adrenal hyperplasia: basic physiology, clinical presentation and management.

Authors:  N G Greger; S K Varma
Journal:  Indian J Pediatr       Date:  1987 May-Jun       Impact factor: 1.967

3.  Congenital adrenal hyperplasia due to combined 21- and 11 beta-hydroxylase deficiency.

Authors:  R Penny; P Vecsei
Journal:  J Endocrinol Invest       Date:  1989-11       Impact factor: 4.256

4.  Corticosterone methyl oxidase type II deficiency: a cause of failure to thrive and recurrent dehydration in early infancy.

Authors:  P Picco; L Garibaldi; M Cotellessa; M DiRocco; C Borrone
Journal:  Eur J Pediatr       Date:  1992-03       Impact factor: 3.183

5.  Perineal reconstruction in ambiguous genitalia infants raised as females.

Authors:  P K Donahoe; W H Hendren
Journal:  Ann Surg       Date:  1984-09       Impact factor: 12.969

6.  Pseudotumor cerebri in a boy with 11-beta-hydroxylase deficiency--a possible relation to rapid steroid withdrawal.

Authors:  Z Zadik; Y Barak; D Stager; H Kaufman; S Levin; N Gadoth
Journal:  Childs Nerv Syst       Date:  1985       Impact factor: 1.475

7.  Salt loss in congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency.

Authors:  Z Hochberg; A Benderly; Z Zadik
Journal:  Arch Dis Child       Date:  1984-11       Impact factor: 3.791

Review 8.  Insights on the phenotypic heterogenity of 11β-hydroxylase deficiency: clinical and genetic studies in two novel families.

Authors:  Luciana Pinto Valadares; Alessandra Christine Vieira Pfeilsticker; Selma Moreira de Brito Sousa; Sarah Caixeta Cardoso; Olivia Laquis de Moraes; Luiz Claudio Gonçalves de Castro; Renata Santarem de Oliveira; Adriana Lofrano-Porto
Journal:  Endocrine       Date:  2018-09-21       Impact factor: 3.633

9.  Adrenal hypoplasia congenita presenting as congenital adrenal hyperplasia.

Authors:  Jennifer L Flint; Jill D Jacobson
Journal:  Case Rep Endocrinol       Date:  2013-02-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.